PT-141 vs Melanotan II
Both PT-141 and Melanotan II are used for sexual-health. Here's how their evidence, dosing, and regulatory status actually compare.
PT-141
Evidence ABremelanotide (Vyleesi)
A melanocortin receptor agonist that works directly on the nervous system to increase sexual desire. The only FDA-approved peptide for sexual dysfunction that acts on the brain rather than vascular system.
View full PT-141 profile →Melanotan II
Evidence C+Melanotan II (MT-II)
A non-selective melanocortin agonist (MC1R/MC3R/MC4R) that produces tanning and erection effects. Significant safety concerns including melanoma case reports.
View full Melanotan II profile →Side-by-Side
| Attribute | PT-141 | Melanotan II |
|---|---|---|
| Evidence Grade | A | C+ |
| FDA Status | FDA-approved for hypoactive sexual desire disorder (HSDD) in women | Not FDA-approved — sold illegally as cosmetic; FDA warning letters issued |
| Typical Dose | 1.75 mg subcutaneous, 45 min before activity | 0.25–1 mg daily during loading, then maintenance (subcutaneous) |
| Clinics Indexed | 210 | 18 |
| Categories | sexual-health | skin, sexual-health |
Key reported benefits — PT-141
- ✓Increased sexual desire
- ✓CNS-mediated arousal
- ✓Works for both sexes (off-label for men)
Key reported benefits — Melanotan II
- ✓UV-independent tanning
- ✓Erectile effect (off-label)
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.